NCT02303444 2023-06-08
RIFTOS MKI
Bayer
Completed
Clinical Trials
6 trialsNCT02084732 2019-11-13
Safety and Efficacy of Sorafenib in Patients With Advanced Thyroid Cancer: a Phase II Clinical Study
Instituto Nacional de Cancerologia, Columbia
Phase 2 Completed
NCT00984282 2018-09-13
Nexavar® Versus Placebo in Locally Advanced/Metastatic RAI-Refractory Differentiated Thyroid Cancer
Bayer
Phase 3 Completed
NCT01025453 2018-08-15
Combination of Temsirolimus and Sorafenib in the Treatment of Radioactive Iodine Refractory Thyroid Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT02114658 2017-08-03
Sorafenib Phase II Study for Japanese Anaplastic or Medullary Thyroid Carcinoma Patients
Bayer
Phase 2 Completed
NCT00887107 2009-04-23
Sorafenib as Adjuvant to Radioiodine Therapy in Non-Medullary Thyroid Carcinoma
Leiden University Medical Center
Phase 2 Completed